<DOC>
	<DOCNO>NCT01367574</DOCNO>
	<brief_summary>This double-blind , randomize , parallel group , dose range study subcutaneous methylnaltrexone conduct patient advanced medical illness poorly control opioid induce constipation . Patients randomize one three fix dose level SC MNTX .</brief_summary>
	<brief_title>Methylnaltrexone Patients With Opioid-Induced Bowel Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<criteria>1 . Must advance medical illness ( cancer , HIV , etc ) receive palliative care 2 . Must opioid medication least 2 week expectation significant change regimen 3 . Must constipation 4 . Must 18 yr old 1 . Concurrent use medication opioids might interfere gastrointestinal motility 2 . Patients receive experimental drug last 30 day 3 . Patients active peritoneal cancer ( ovarian , etc . ) 4 . Patients active diverticulitis diverticulosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Opioid-induced bowel dysfunction</keyword>
</DOC>